The goal of this clinical trial is to determine if carfilzomib, lenalidomide and dexamethasone are safe and effective in treating high-risk smoldering multiple myeloma.
This trial is currently open and accepting patients.
This study is organized into 28 day cycles, with patients scheduled to receive:
After the first 4 cycles (approximately 4 months), stem cell transplant eligible patients may decide to have their stem cells collected and stored. After the initial 8 cycles (approximately 8 months), patients whose smoldering myeloma has not gotten worse may have up to 12 additional cycles of oral lenalidomide alone.
Enrollment: 30 patients (estimated)View More
If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.
You can explore trial locations from around the US and connect directly with a trial coordinator.Find Nearby Locations
You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.
Still need help? Send us a message
The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required. Create your account or call us today for help (888) 828-2206.
View all clinical trial locations sorted by state.